Kaldjian et al. (2015) [68] used the same platform, AccuCyte-CyteFinder, to identify CTCs in advanced prostate cancer patients and compare CTC counts with the FDA-cleared CellSearch system (system based on automated immuno-magnetic capture of EpCAM-expressing cells, followed by staining for DNA and cytokeratin to verify that captured cells are nucleated and epithelial in origin) [62,64,68]. This evidence concerns the gene EPCAM and Familial prostate cancer.